Subjects from the PIONNEER 7 study showed comparable satisfaction between oral semaglutide and sitagliptin [41], a dipeptidyl peptidase-4 inhibitor (DPP-4i) largely used in monotherapy or combination when first-line treatment does not achieve adequate glycaemic control, but sitagliptin does not provide any cardiovascular benefit [95]
Common side effects may include: Early fullness (feeling satisfied sooner while eating) Bloating or mild stomach discomfort Heartburn or indigestion Constipation or, less commonly, loose stools If symptoms occur, they often improve by eating smaller meals, slowing your pace while eating, drinking plenty of water, and limiting greasy or high-fat foods
Materials and Methods Cell Line and Cell Treatment INS-1 cells were procured from the National Infrastructure of Cell Line Resource (Beijing, China) and cultured in RPMI-1640 (Invitrogen, Carlsbad, CA, United States) added with L-glutamine, FBS (10%
Prevention of cardiorenal complications in people with type 2 diabetes and obesity
What does this mean for their long-term health
The FDA is also tracking some adverse event reports that starting GLP-1 treatment caused or exacerbated serious psychiatric conditions associated with depression and suicidality
